# Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

> **NCT05248646** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 530 (actual)

## Conditions studied

- Immunoglobulin A Nephropathy

## Interventions

- **DRUG:** Sibeprenlimab 400 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05248646
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-15
- **Primary completion:** 2026-05-07
- **Final completion:** 2026-12-30
- **Target enrollment:** 530 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248646, "Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05248646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*